Categories
Politics

Kamala Harris fundraiser Jon Henes to launch company advisory agency

Vice President Kamala Harris’ former national campaign finance chair is opening a strategic advisory firm that will aim, in part, to guide corporations and C-suite executives through handling social justice and politically charged issues.

Jon Henes, a longtime corporate restructuring attorney at the prominent law firm Kirkland & Ellis, plans to launch his new New York-based firm around Labor Day, according to people briefed on the matter.

The firm is planning to hire at least 15 people at first, and it could expand operations to Washington, D.C., Los Angeles and San Francisco, a person said.

The advisory firm will have a multipronged approach, including a corporate strategic advisory arm that would do the traditional counseling on hiring practices such as union inclusion. It will also have a team that will focus on environmental, social and corporate governance, and workplace diversity, equity and inclusion, these people said.

The people cited in this story declined to be named because details for the new venture have yet to be finalized.

A Kirkland & Ellis press release announcing Henes’ departure noted he was on his way to starting a strategic advisory firm but provided no further details.

“Over the past few years, in addition to my work at Kirkland, I have had the opportunity to immerse myself in the world of politics and policy, opening my eyes to the critical business need for helping CEOs navigate the convergence of business, finance and law with social justice, diversity, inclusion and politics,” Henes said in the release. “It is bittersweet to leave my Kirkland colleagues, many of whom I think of as family, but I’m excited to embark on this new chapter of my career.”

He did not return CNBC’s follow-up requests for comment.

The firm’s launch comes as corporations experience pushback from consumers and employees over their stances on social justice and environmental issues.

After voting laws that have been deemed restrictive by critics were passed in Georgia, corporations felt pressured to respond. Several did, including Major League Baseball, which moved its All-Star Game from Georgia to Colorado.

In a recent example of the pressure, Toyota halted giving campaign contributions to Republican lawmakers who challenged the results of the election.

The competition for advisory firms like these is fierce, but many, especially those run by people with high-level contacts, are often successful.

Teneo, which was co-founded by Bill Clinton’s former right-hand man, Doug Band, has been known as an influential advisory group that has links to massive corporations.

The same can be said for WestExec Advisors, which has seen over 15 consultants head into the Biden administration, according to reporting by The Intercept and The American Prospect. Antony Blinken co-founded WestExec and is now secretary of State.

One of the other expected leaders of Henes’ firm is Alvin Tillery, according to the sources. Tillery is an associate professor at Northwestern University and director of the school’s Center for the Study of Diversity and Democracy.

Tillery has experience running an advisory firm of his own. He is the founder of Analytic Insights Consulting, which, according to the firm’s website, “advises corporate, nonprofit, and governmental entities seeking to build more diverse, equitable, and inclusive work environments.” The firm’s listed previous clients include MGM International Resorts, Baker Demonstration School, the City of Evanston, and Exelixis.

If Tillery and Henes reach an official agreement, Tillery would continue his work at the school and will have a leadership role at the newly created advisory business, a person said. Analytic Insights Consulting is potentially folded into the new firm founded by Henes, this person noted.

Tillery did not respond to a request for comment.

Henes was Harris’ national finance chair while she was running for president during the 2020 election, helping her raise at least $400,000 before he started raising money for Joe Biden, CNBC previously reported.

Henes also led fundraising efforts both for Democrat Jaime Harrison’s bid for South Carolina’s U.S. Senate seat last year and former Citigroup executive Ray McGuire’s campaign for New York mayor in the Democratic primary this year.

While the Harris, Harrison and McGuire runs were unsuccessful, his fundraising efforts were key for Henes in developing contacts and potential partners and clients for his new firms. Harris went on to be vice president, and Harrison is the new chair of the Democratic National Committee.

Henes also developed strong corporate ties when he worked for clients as a restructuring and corporate governance advisor. Kirkland’s website shows that his past clients include Ion Media, Avaya and J.Jill.

Categories
Health

Physician on CDC advisory panel expects pause lifted

A member of a key CDC advisory body told CNBC Friday morning that he expects the U.S. hiatus on Johnson & Johnson’s one-off coronavirus vaccine to be lifted at some point.

“I think we are ready to use this vaccine. We had to take an important pause to review this safety information to consider the risks. But I think there is a large amount of evidence that the Benefit far outweighs this risk, “said Dr. Wilbur Chen, professor in the University of Maryland School of Medicine.

Chen spoke on the Worldwide Exchange before attending a meeting of the Agency’s Advisory Committee on Immunization Practices later on Friday to discuss the rare but serious bleeding disorder some women had after receiving the J&J shot.

In addition to the six patients who experienced rare but severe blood clotting problems after receiving the vaccine, the CDC is investigating two other possible cases: a deceased Oregon woman and a Texas woman who was hospitalized. Of the original six women, one died and one became seriously ill. Approximately 8 million J&J vaccine doses have been administered.

Concern over the problem led the Centers for Disease Control and Prevention and the FDA to temporarily stop using the J&J vaccine in the US last week. When asked by CNBC’s Brian Sullivan whether he believes Americans will get the J&J vaccine at some point, Chen said, “Yes.”

The Advisory Committee on Immunization Practices, known as ACIP, is an external panel of experts that makes recommendations to the CDC. A meeting on the J&J vaccine was called last week, but a decision was postponed until this week. Ultimately, it is up to the CDC and the Food and Drug Administration what to do next.

Chen said ACIP now has better information about the blood clotting problems on which to base its vaccination instructions. “We’ll be able to get a good sample size. It may not be perfect, but we don’t have to be perfect to have actionable information,” said Chen, adding that he expects the panel to “get a number.” working out of recommendations that I think everyone will be happy with. “

In a statement emailed to CNBC, CDC Director Dr. Rochelle Walensky, she hopes the Public Health Agency will receive a “recommendation” that considers the risk versus benefit of using the Johnson & Johnson vaccine based on the new case data and the risk-benefit ratio analysis CDC has in last week. “

“I really appreciate the complex issue before the committee and look forward to hearing from you. I also appreciate the importance of working with the FDA to act quickly as soon as we hear about ACIP,” added Walensky .

Given the urgency of the coronavirus pandemic, some people have criticized the decision to discontinue the J&J Covid vaccine – which only requires one dose for full immunity protection – while the clot investigation was in progress.

Chen disagreed.

“The risk is very, very small, but until we could fully take into account this information we haven’t been able to contextualize this for the rest of the medical community and the public too,” he said. “We only took a 10-day break. Hopefully this won’t be detrimental in the long term, but we obviously want to instill confidence in the security information collection system.”

The other two emergency-approved Covid vaccines in the US come from Pfizer and Moderna. Both require two shots.

Categories
Health

FDA advisory panel meets at this time to vote on whether or not to advocate approval of Pfizer’s Covid vaccine

[The stream is slated to start at 9 a.m. ET. Please refresh the page if you do not see a player above at that time.]

A panel from the Food and Drug Administration will meet Thursday to vote on whether to recommend Pfizer and BioNTech’s emergency approval of the coronavirus vaccine.

Prior to voting by the Agency’s Advisory Committee on Vaccines and Related Biological Products, the independent panel of medical experts will evaluate the Pfizer clinical trial data and provide their opinion on the vaccine, including whether the benefits outweigh the risks in an emergency .

The FDA is not required to follow the advice of the advisory group, but it often does.

A recommendation from the advisory committee is the final step before the FDA is likely to give final OK to the distribution of the potentially life-saving doses in the United States. The vaccine would be the first to be approved for use in the United States

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.